<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915235</url>
  </required_header>
  <id_info>
    <org_study_id>PAPCAT</org_study_id>
    <nct_id>NCT04915235</nct_id>
  </id_info>
  <brief_title>Prevalence and Prognosis of Cardiac Amiloidosis in Turkey</brief_title>
  <acronym>PAPCAT</acronym>
  <official_title>Prevalence and Prognosis of Cardiac Amiloidosis in Turkey- Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turkish Society of Cardiology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turkish Society of Cardiology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with left ventricular hypertrophy are further examined according to an algorithm to&#xD;
      check if they have a cardiac amyloidosis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Cardiac Amyloidosis</measure>
    <time_frame>Upon screening</time_frame>
    <description>Patients with left ventricular hypertrophy and Cardiac Amyloidosis</description>
  </primary_outcome>
  <enrollment type="Anticipated">2087</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Algorithm</intervention_name>
    <description>Algorithm</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with left ventricular hypertrophy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with left ventricular hypertrophy without left ventricular pressure or volume&#xD;
             (IVSâ‰¥13mm)&#xD;
&#xD;
          -  Patients with left ventricular hypertrophy and hypertension or aortic stenosis without&#xD;
             left ventricular pressure or volume (IVS&gt;15mm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with left ventricular pressure or volume except the ones with aortic stenosis&#xD;
             and arterial hypertension&#xD;
&#xD;
          -  Patients with sigmoid septum and their hypertrophy limited in sigmoid area&#xD;
&#xD;
          -  Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LV&#xD;
             morhpology and genetic testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilkay Gucuk, MD</last_name>
    <phone>902122211738</phone>
    <email>tkd@tkd.org.tr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dokuz Eylul University Faculty of Medicine</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ebru Ozpelit, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>May 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

